RxDoctor Payments Data

Amanda Austin

Family · Oklahoma City, OKNPI 1407385560

Payments from drug & device makers

$2,817in general payments, 2019–2025

Across 143 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$432
  • Boehringer Ingelheim$413
  • Merck$398
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$394
  • Pfizer$352
  • Novartis$252
  • plus $576 from 9 others

What the payments were for

  • Food & beverage$2,817100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,817 in reported general payments places this provider in the 85th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$24,552
Medicare patients
234
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban260$291,085
EntrestoSacubitril/Valsartan122$154,634
JardianceEmpagliflozin70$93,266
FarxigaDapagliflozin Propanediol56$71,493
MultaqDronedarone Hcl30$34,364
Repatha SureclickEvolocumab49$32,095
XareltoRivaroxaban15$14,795
Atorvastatin Calcium471$5,685
Bisoprolol Fumarate177$5,613
Rosuvastatin Calcium179$3,956
Metoprolol Succinate349$3,844
Nebivolol Hcl53$3,311
ClopidogrelClopidogrel Bisulfate206$2,773
Losartan Potassium236$2,758
Potassium Chloride99$2,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$352$291,085260 claims
NovartisEntresto$252$154,634122 claims
Boehringer IngelheimJardiance$413$93,26670 claims
AstraZenecaFarxiga$148$71,49356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,026 family providers in Oklahoma.

Other family in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →